Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali Kaplan

Showing results (141-150 of 149) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 149 results.
Journal of Chemotherapy (Florence, Italy)|September 11, 2024
Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinomaHasan Cagri Yildirim, Ertuğrul Bayram, Elvin Chalabiyev, et al.
Immunotherapy|April 21, 2026
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumabAli Kaan Güren, Nazım Can Demircan, Özge Gümüşay, et al.
Journal of Cancer Research and Clinical Oncology|April 17, 2023
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) studyAhmet Bilici, Sinan Koca, Mustafa Karaagac, et al.
Scientific Reports|March 9, 2024
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesSeda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 18, 2020
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patientsNir Peled, Roni Gillis, Saadettin Kilickap, et al.
Journal of Chemotherapy (Florence, Italy)|January 24, 2024
The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencingOsman Köstek, Ahmet Demirel, Muhammet Bekir Hacıoğlu, et al.
Clinical Genitourinary Cancer|June 25, 2026
Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the LiteratureCevat İlteriş Kıkılı, Murat Araz, Yüksel Ürün, et al.
Discover Oncology|March 23, 2026
Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective studyOsman Sütcüoğlu, Orhun Akdoğan, İlknur Deliktaş Onur, et al.
Cancers|June 26, 2026
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group StudyBahadır Köylü, Özde Melisa Celayir, Harun Muğlu, et al.
Pageof 15

Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Journal of Chemotherapy (Florence, Italy)|September 11, 2024
Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinomaHasan Cagri Yildirim, Ertuğrul Bayram, Elvin Chalabiyev, et al.
Immunotherapy|April 21, 2026
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumabAli Kaan Güren, Nazım Can Demircan, Özge Gümüşay, et al.
Journal of Cancer Research and Clinical Oncology|April 17, 2023
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) studyAhmet Bilici, Sinan Koca, Mustafa Karaagac, et al.
Scientific Reports|March 9, 2024
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesSeda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 18, 2020
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patientsNir Peled, Roni Gillis, Saadettin Kilickap, et al.
Journal of Chemotherapy (Florence, Italy)|January 24, 2024
The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencingOsman Köstek, Ahmet Demirel, Muhammet Bekir Hacıoğlu, et al.
Clinical Genitourinary Cancer|June 25, 2026
Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the LiteratureCevat İlteriş Kıkılı, Murat Araz, Yüksel Ürün, et al.
Discover Oncology|March 23, 2026
Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective studyOsman Sütcüoğlu, Orhun Akdoğan, İlknur Deliktaş Onur, et al.
Cancers|June 26, 2026
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group StudyBahadır Köylü, Özde Melisa Celayir, Harun Muğlu, et al.
Pageof 15